Article
Oncology
J. Randolph Hecht, Sara Lonardi, Johanna Bendell, Hao-Wen Sim, Teresa Macarulla, Charles D. Lopez, Eric Van Cutsem, Andres J. Munoz Martin, Joon Oh Park, Richard Greil, Hong Wang, Rebecca R. Hozak, Ivelina Gueorguieva, Yong Lin, Sujata Rao, Baek-Yeol Ryoo
Summary: The study found that adding PEG to FOLFOX did not improve efficacy in patients with metastatic pancreatic ductal adenocarcinoma, and the safety profiles of the two treatment arms were similar.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Endocrinology & Metabolism
Salvatore Grisanti, Deborah Cosentini, Marta Lagana, Alessandra Morandi, Barbara Lazzari, Laura Ferrari, Alberto Dalla Volta, Roberta Ambrosini, Vittorio Domenico Ferrari, Sandra Sigala, Alfredo Berruti
Summary: The Gem/Cape chemotherapy regimen shows modest activity in heavily pretreated patients with adrenocortical carcinoma. Clinical parameters such as neutrophil-to-lymphocyte ratio (NLR) and ECOG performance status are helpful in identifying patients who are unlikely to benefit significantly from this treatment.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Se-Il Go, Sang-Cheol Lee, Woo Kyun Bae, Dae Young Zang, Hyun Woo Lee, Joung Soon Jang, Jun Ho Ji, Jung Hoon Kim, Sanggon Park, Sun Jin Sym, Yaewon Yang, So Yeon Jeon, In Gyu Hwang, Sung Yong Oh, Jung Hun Kang
Summary: The study shows that using mFOLFIRINOX as a second-line chemotherapy treatment for mPAC patients refractory to gemcitabine-based chemotherapy resulted in significantly increased survival rates.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Esther N. Pijnappel, Willemieke P. M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W. M. van Laarhoven, Johanna W. Wilmink
Summary: This study investigated the use of first- and second-line systemic treatments and survival outcomes in patients with metastatic PDAC. The findings suggest that FOLFIRINOX as first-line treatment provides superior overall survival compared to gemcitabine with or without nab-paclitaxel.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Article
Multidisciplinary Sciences
Masaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Tomoyuki Ushijima, Keisuke Miwa, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Tsuyoshi Shirakawa
Summary: This study investigated the survival and efficacy of different chemotherapy regimens in patients with metastatic pancreatic cancer. The results showed that second-line chemotherapy was associated with longer overall survival compared to best supportive care. However, there was no significant difference in survival between combination chemotherapy and mono chemotherapy in the second-line treatment.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Lei Yang, Jing Su, Wenbo Wang, Fuxiang Zhou
Summary: In this study, the efficacy and safety of AG and FFX as first-line chemotherapy regimens in Chinese patients with metastatic pancreatic cancer were compared. The results indicate that AG and FFX have comparable efficacy outcomes, and patients with good nutritional status have a better prognosis.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Shun Yamamoto, Kengo Nagashima, Takeshi Kawakami, Seiichiro Mitani, Masato Komoda, Yasushi Tsuji, Naoki Izawa, Kentaro Kawakami, Yoshiyuki Yamamoto, Akitaka Makiyama, Kentaro Yamazaki, Toshiki Masuishi, Taito Esaki, Takako Eguchi Nakajima, Hiroyuki Okuda, Toshikazu Moriwaki, Narikazu Boku
Summary: This study found that in mCRC patients, those who experienced early progression in first-line chemotherapy showed poor clinical outcomes with second-line chemotherapy regardless of the use of anti-angiogenic agents.
Article
Medicine, General & Internal
Avital Klein-Brill, Shlomit Amar-Farkash, Gabriella Lawrence, Eric A. Collisson, Dvir Aran
Summary: This study compared the two common first-line treatments for metastatic adenocarcinoma of the pancreas, FOLFIRINOX and gemcitabine plus nab-paclitaxel, and found that FOLFIRINOX was associated with improved overall survival and fewer posttreatment complications.
Review
Oncology
Francesco Di Costanzo, Federica Di Costanzo, Lorenzo Antonuzzo, Ernesto Mazza, Elisa Giommoni
Summary: Choosing the best first-line treatment for metastatic pancreatic cancer is crucial in improving survival rate and quality of life. FOLFIRINOX and Nab-p plus Gem have been recognized as the most effective treatment regimens. FOLFIRINOX shows better efficacy but higher toxicity.
Review
Medicine, Research & Experimental
Wenjie Lu, Lantian Wang, Xiawei Li, Kezhong Tang
Summary: This meta-analysis evaluates the treatment effects of different second-line chemotherapy regimens compared to FOLFIRINOX in patients with pancreatic cancer after failure of gemcitabine-based first-line therapy. The results indicate that FOLFIRINOX has a longer progression-free survival and overall survival, as well as a better objective response rate and disease control rate compared to the other regimens. However, grade 3/4 adverse events are more commonly reported in patients treated with FOLFIRINOX.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
(2022)
Article
Oncology
Sam Z. Thalji, Mandana Kamgar, Ben George, Mohammed Aldakkak, Kathleen K. Christians, Callisia N. Clarke, Beth A. Erickson, William A. Hall, Parag P. Tolat, Zachary L. Smith, Douglas B. Evans, Susan Tsai
Summary: This study investigated the response of carbohydrate antigen 19-9 (CA19-9) to first-line and second-line chemotherapy in patients with operable pancreatic cancer. The study found that patients with no biochemical response after 2 months of first-line chemotherapy have a high rate of response to second-line chemotherapy.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Mitesh J. Borad, Li-Yuan Bai, Donald Richards, Kabir Mody, Joleen Hubbard, Sun Young Rha, John Soong, Daniel McCormick, Emmett Tse, Daniel O'Brien, Ahmad Bayat, Daniel Ahn, S. Lindsey Davis, Joon Oh Park, Do-Youn Oh
Summary: This study investigates the safety and efficacy of silmitasertib in combination with gemcitabine and cisplatin for the treatment of cholangiocarcinoma. The results show promising preliminary evidence of efficacy for the first-line treatment of locally advanced/metastatic cholangiocarcinoma.
Article
Oncology
Takafumi Mie, Takashi Sasaki, Takeshi Okamoto, Tsuyoshi Takeda, Chinatsu Mori, Takaaki Furukawa, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahira
Summary: This study compared the efficacy and adverse events of nanoliposomal-irinotecan plus fluorouracil and leucovorin and modified FOLFIRINOX as second-line treatment for metastatic and recurrent pancreatic cancer after gemcitabine with nab-paclitaxel. The results showed no significant difference in efficacy between the two treatment options.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Jiayuan Chen, Qingling Hua, Haihong Wang, Dejun Zhang, Lei Zhao, Dandan Yu, Guoliang Pi, Tao Zhang, Zhenyu Lin
Summary: The study found that modified FOLFIRINOX and GEM-NAB had similar survival and toxicity profiles, with GEM-NAB showing greater efficacy in terms of objective response rate. Therefore, various factors should be considered when formulating optimal treatment strategies for advanced pancreatic cancer.
Article
Oncology
Hsiao-Ling Chen, Vinson Wai-Shun Chan, Yu-Kang Tu, Erica On-Ting Chan, Hsiu-Mei Chang, Yung-Shun Juan, Jeremy Yuen-Chun Teoh, Hsiang Ying Lee
Summary: In the context of first-line treatment for metastatic urothelial carcinoma (mUC), combination therapy involving immune checkpoint inhibitors (ICIs) showed superior overall survival compared to monotherapy, while ICIs alone demonstrated non-inferiority to chemotherapy (CTX) in terms of survival benefit. Additionally, the tolerability of ICIs was found to be high, with combination therapy not increasing the risk of severe adverse events when compared to CTX.